Information Provided By:
Fly News Breaks for April 5, 2016
ICPT
Apr 5, 2016 | 10:57 EDT
FBR Capital analyst Vernon Bernardino views the FDA briefing documents for Intercept Pharmaceuticals' obeticholic acid for the treatment of primary biliary cholangitis as mostly in line. The analyst views the data as "robust enough" to support OCA's approval, but he points out the FDA requested discussion on the use of OCA in more advanced stages of PBC and hepatic impairment. Bernardino has a Market Perform rating on Intercept shares.
News For ICPT From the Last 2 Days
There are no results for your query ICPT
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.